Future Targets For NMRD
TARGET: Obtain FDA approval for sugarBEAT®
TARGET: Scale-up manufacture to support sales in UK, Europe & and Middle East through licensees
TARGET: Build market share in USA with employers and insurers, for the BEAT®diabetes and Miboko (non-medical) programs. Scaled-up Pilot programs in June 2023
TARGET: Launch sugarBEAT® ‘Direct-to-Consumer’ in all major territories accepting CE approval as part of product registration; Discussions in multiple territories ongoing
TARGET: Commercial exploitation of the metabolic health and wellbeing market using the sensors, initially targeting over 87 million people in the USA with pre-diabetes
With the future looking extremely bright for Nemaura Medical Inc. (NMRD), now may be the perfect time to do a deeper dive into the company's ins an outs.
Grab Key Sources Here: Company Presentation. Company Website.
-----
As mentioned above, NMRD has several potential breakout catalysts to focus on immediately. Take a look:
No. 1 NMRD Potential Catalyst - Interim Results From Miboko Program Holds Eye-Catching Retention Rates
Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program
LOUGHBOROUGH, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced interim results from its metabolic health program.
The primary objective of the study was to establish whether a metabolic program with a daily wear CGM worn twice a month resulted in greater engagement levels and sustainable weight reduction, and how this compared to other programs. The multi-centered study was run in collaboration with the UK’s National Health Service.
Known as Miboko (Mind, Body, Konnect), the program is the first to integrate a daily-wear and non-invasive glucose sensor with the Company’s bespoke app, educational content and AI driven analytics platform.
...
The study tracked 83 participants, with a mean age of 54 years old. The cohort was made up of 67% female (F), and 33% male (M), and 88% of participants recorded their ethnicity as ‘White’. After 20 weeks of enrollment, 59 people (16M/43F) had recorded weight loss, with 21 participants losing over 5KG (11 pounds). On an average basis, weight loss was 2.9KG (6.3 pounds) (1.9M/3.2F), with the rate of change increasing after week 8.
Qualitative feedback from users demonstrated substantially increased levels of understanding and empowerment on their weight loss goals, correlating to long-term behavioural changes that are pivotal to sustained weight loss. Of particular note is that users derived considerable benefit from their personalised insights, based on their Metascore® and response to diet and exercise. Verbatims from users confirmed that CGM sensor use increased user participation, better understanding of food choices and portion size.
After 20 weeks of use, the program had a retention rate of 32.5%. When active participants were asked whether they would continue with the program, 64% of respondents stated they were likely or very likely to continue to use the program. This far exceeds retention rates for health and wellbeing apps of 16.7% at 13 weeks and 6.9% at 26 weeks.
Published studies report that affordability is a key barrier to CGM adoption, and the Company aims to price its CGM-embedded program significantly lower than any presently available comparable program.
The integration of Nemaura’s CGM sensor means that for the first time, a low-cost metabolic health improvement prevention program will soon be commercially available. The Company has the advantage of its own proprietary non-invasive sensor technology, which significantly reduces sensor costs, as the sensors are only worn a few days each month.
...
Read the full article here.
-----
No. 2 NMRD Potential Catalyst - NMRD's Low Float Suggests Volatile Potential
According to the Yahoo Finance website, NMRD has a relatively low float.
The website reports this profile to have roughly 12.33Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more positive company news towards the end of 2023 provide a breakout spark?
-----
No. 3 NMRD Potential Catalyst - sugarBEAT® Receives SFDA Approval (Huge News For Commercialization Efforts)
Nemaura Medical Announces SFDA Approval of sugarBEAT®
Loughborough, England, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today announced SFDA (Saudi Food and Drug Authority) approval of sugarBEAT®, its non-invasive wearable glucose sensor.
The news comes following over a year of liaisons with the SFDA through TPMENA, the Company’s licensee in the Middle East, and is seen as a major breakthrough in product commercialisation in the largest territory in the Middle East, and a region with one of the world’s highest diabetes prevalence rates.
In 2021, the Economist Intelligence Unit published a report titled ‘Telemedicine and Diabetes Care in Saudi Arabia and the UAE’, which examined the diverse government subsidized initiatives being taken to manage and reverse the diabetes epidemic in the region. The report states that nearly 4.5 million people, or 18.3% of the adult population in Saudi Arabia, have diabetes, compared to a global average of 9.3%. Mordor Intelligence has reported that the market size for diabetes related care devices in Saudi Arabia is expected to grow from $637Mn in 2023 to $788Mn in 2028.
Furthermore, it is estimated that 39% of adults with diabetes in Saudi Arabia are unaware that they have the condition, leaving them at higher risk of complications without management. This segment of nearly 9 million people is ideally placed to benefit from sugarBEAT® sensors within a general metabolic health improvement program. Such a program specifically addresses obesity to avoid diabetes and other complications and has shown efficacy within trials with the UK’s National Health Service.
The Company previously announced the receipt of a provisional purchase order for 1.7 million sensors and 17,000 devices from TPMENA. The Company will now work with its licensee to commence fulfilling this purchase order.
...
Read the full article here.
-----
No. 4 NMRD Potential Catalyst - Corporate Highlights Paint Nemaura To Be Hurdling Towards Bright Future
Nemaura Medical Reports Fi-nan-cial Results and Provides Business Update for the Fiscal Year Ended March 31, 2023
Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today provides a business update and fi-nan-cial results for the fiscal year ended March 31, 2023.
Corporate Highlights:
- Entered into a Registered Direct Offering and concurrent Private Placement for gross proceeds of approximately $8.4Mn (before expenses).
- Signed a preliminary agreement with Eversana to support a planned commercial launch of its Diabetes and Metabolic Health programs in the USA.
- Announced initial patient data from UK NHS (National Health Service) Miboko Study that thus far demonstrated weight loss in 100% of participants, with further studies ongoing. The data is expected to support reimbursement applications and product marketing in various territories.
- Continued to work with Benchmark Electronics Inc as a contract manufacturing partner (CMO) to facilitate future volume scale-up manufacture of the electronic transmitter at its FDA approved facility in Thailand, in anticipation of commercial-sales ramp-up.
- Completed phased delivery of transmitters against the purchase order received from MSW in December 2021.
- Received a provisional purchase order for 1.7 million sensors from its licensee TPMENA in anticipation of product registration in the KSA.
“We continue to build momentum on both manufacturing activities and consumer feedback through pilot trials, in preparation for scaling up commercial sales activities. The trials with the NHS in the UK have demonstrated the commercial potential for our sensors and digital health and wellbeing programs and has allowed us to undertake continuous refinements prior to commercial scale-up initiatives. Similarly, we believe working with world-class contract manufacturers and advancing our manufacture scale-up, and ensuring a well-managed supply chain through forward planning will support our planned commercial endeavours,” commented Dr Faz Chowdhury, CEO of Nemaura medical. “During the new fiscal year our focus is on global partnerships and revenue ramp-up, leveraging off the progress we have made on the product refinement and feedback, and product manufacture."
...
Read the full article here.
-----
No. 5 NMRD Potential Catalyst - NMRD Hits The Gas On Pilot Expansion Of proBEAT™ (Huge Step Towards Revenue Generation)
Nemaura Medical Scales-Up Pilot Expansion of proBEAT™; 56 Corporations in the U.S. Signed Up for Pilots in June 2023
LOUGHBOROUGH, June 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on non-invasive wearable sensors and personalized weight reduction programs, announces the next commercialization stage of its proBEAT™ sensor and AI-based feedback platform, augmenting the BEAT™diabetes program. The pilots are intended as a precursor to revenue generating contracts for proBEAT™ and will commence over the coming weeks and months. The Company is continuing its discussions with corporations and health insurers in the U.S. to further increase the number of pilots that will run in calendar year 2023.
Dr. Faz Chowdhury, Nemaura’s Chief Executive Officer, stated, “The expansion of the BEATdiabetes program into employers and insurers in the U.S. represents significant progress towards bringing more innovative diabetes care solutions to our target markets. Importantly to Nemaura, this is a big step toward revenue generation with our proBEAT™ platform, and we aim to continue the momentum over the coming months and years. We spent a vast amount of time and resources optimizing and scaling our sensor manufacturing processes and it’s extremely fulfilling for the team to see their hard work come to fruition through these developments, bringing cost-effective solutions to the market.”
...
Read the full article here.
-----
NMRD Recap - 5 Key Potential Catalysts To Watch Right Now
No. 1 - Interim Results From Miboko Program Holds Eye-Catching Retention Rates
No. 2 - NMRD's Low Float Suggests Volatile Potential
No. 3 - sugarBEAT® Receives SFDA Approval (Huge News For Commercialization Efforts)
No. 4 - Corporate Highlights Paint Nemaura To Be Hurdling Towards Bright Future
No. 5 - NMRD Hits The Gas On Pilot Expansion Of proBEAT™ (Huge Step Towards Revenue Generation)
-----
Coverage is officially initiated on NMRD. When time allows, do this:
